Αποτελέσματα Αναζήτησης
28 Αυγ 2020 · Indications. Milrinone is a medication indicated for cardiac support in patients with acute heart failure, pulmonary hypertension, or chronic heart failure. It improves cardiac contractility (inotropy) and cardiac relaxation (lusitropy) and induces vasodilation.
Milrinone is a PDE-III inhibitor with inotropic, lusitropic, and vasodilatory properties used for the short-term treatment of acute decompensated heart failure. Generic Name. Milrinone. DrugBank Accession Number. DB00235. Background. Heart failure is a multifactorial condition that affects roughly 1-2% of the adult population.
Milrinone is a nonglycoside, nonbeta-adrenergic positive inotropic agent that was introduced recently for the treatment of CHF.
7 Ιουλ 2020 · The Mil HFPEF (Extended Release Oral Milrinone for the Treatment of Heart Failure With Preserved Ejection Fraction) study was a randomized, double‐blind, placebo‐controlled pilot study in 23 patients with symptomatic HF p EF.
Milrinone, sold under the brand name Primacor, is a pulmonary vasodilator [2] used in patients who have heart failure. It is a phosphodiesterase 3 inhibitor that works to increase the heart's contractility and decrease pulmonary vascular resistance.
7 Ιουλ 2020 · We hypothesised that modulation of the phosphodiesterase type 3/cyclic AMP using a novel oral formulation of milrinone might exert favorable effects HFpEF via pulmonary and systemic vasodilation and enhancement of ventricular relaxation.
Milrinone inhibits phosphodiesterase 3 in cardiac and smooth muscle tissues, thus increasing cyclic adenosine monophosphate levels and a resultant increase in intracellular ionised calcium. It is a positive inotrope and a systemic and pulmonary arterial vasodilator, with little positive chronotropic effect.
